ASX Stocks to Buy in FY27: Here Are Our Top 10 To Watch!

Today is the first day of the new financial year, and we think plenty of investors are wondering which ASX Stocks to Buy in FY27. Stocks Down Under recaps 10 stocks that it thinks is set for a good 12 months ahead.

10 ASX Stocks to Buy in FY27

Goodman Group (ASX:GMG)

Goodman enters FY27 with the strongest structural tailwinds of any industrial REIT globally. The combination of hyperscaler demand, AI data centre expansion, and constrained industrial land supply has created a multi‑year runway that is largely independent of economic cycles. Goodman’s development workbook has expanded beyond A$18bn, with management signalling that AI‑related data centre projects will represent an increasing share of commencements through FY27. The firm is exposed to AI but in owning land, developing assets, and managing them, rather than developing data centres, fabs or any other capital intensive development related to AI. gives it a vertically integrated advantage that few peers can replicate.

The FY27 story is one of acceleration rather than consolidation. Data centre demand is expected to grow at 20–30% annually, driven by GPU‑dense facilities that require specialised power, cooling, and zoning. Goodman’s ability to secure power allocations in markets such as Sydney, Tokyo, and Frankfurt gives it a competitive moat.  FY27 guidance has not been formally issued, but it is clear that earnings growth will be supported by development completions, rental uplifts, and continued revaluation gains in strategic markets. Goodman remains one of the few ASX names with genuine global tailwinds.

Cochlear (ASX:COH)

Our home-grown cochlear implant maker enters FY27 with demographic momentum, regulatory clarity, and a product cycle that is still in its early innings. The global prevalence of hearing loss continues to rise, driven by ageing populations and improved diagnostic rates. But this year, it is entering on shaky ground given a negative trading update in April led to shares shedding a third of their value in a single day.

In our view, FY27 looks rosier because many of those factors won’t re-occur such as the Middle East disruptions and the strong appreciation of the Australian dollar. And more importantly, two forces have strengthened to provide a good tailwind into the year. The first is that reimbursement environments in the US and Europe have stabilised, reducing volatility in implant volumes. The second is that Cochlear is focusing on out‑innovating rivals, with management signalling increased investment in R&D through FY27 to support next‑generation sound processors and surgical workflows. The firm’s balance sheet remains strong, enabling continued investment without compromising dividends.

Transurban (ASX:TCL)

Transurban’s FY27 narrative is that it has several long-term monopolies over highly-used freeways, especially in Sydney. Toll escalators, many of which are CPI‑linked, providing a natural hedge against inflation. Demographic and structural changes provide a strong tailwind in the form of increased road usage including urban densification. Australia’s population growth remains strong, and urban densification continues to increase road usage.

Moreover, Transurban’s pipeline — including WestConnex optimisation, NorthConnex ramp‑up, and potential future projects in Melbourne; provides multi‑year visibility and diversity beyond Sydney. The firm has also invested heavily in digital tolling and traffic analytics, improving operational efficiency.

Capstone Copper (TSX:CS, ASX:CSC)

We’re copper bulls, in case you didn’t know it and Capstone Copper is one of the few ASX 200 companies offering exposure. Capstone enters FY27 with one of the strongest copper production growth profiles globally – Capstone’s Santo Domingo project, along with expansions at Pinto Valley and Cozamin, position the firm for meaningful volume growth through FY27.

The world’s decarbonisation pathway continues to rely heavily on copper, and supply remains structurally constrained. Demand from electrification, EVs, grid expansion, and renewable infrastructure continues to rise, while new supply remains limited. Capstone’s diversified asset base provides resilience, and the firm’s balance sheet has improved following recent optimisation initiatives.

Pro Medicus (ASX:PME)

We’ve all known the promise of Pro Medicus: its Visage platform continues to differentiate through speed, cloud‑native architecture, and AI‑enabled workflows. The importance of AI in radiology is clear, and Visage positioned as the backbone for diagnostic imaging in high‑volume environments. It has made significant inroads in the US with multi-year, multi-million dollar contracts – many of which include volume‑based pricing that scales over time. And its been making some peculiar investments lately in 4D Medical (ASX:4DX) last July and last month it chipped into EchoIQ. There may be more to come.

So what has held investors back? The valuation. But that isn’t as good an excuse as before given its share price has retreated 39% from all time highs this time last year. But the company has had a strong rally to finish FY26 and we expect the momentum to continue.

Ramsay Health Care (ASX:RHC)

Ramsay enters FY27 with a recovering elective surgery pipeline, stabilising labour costs, and improving operational efficiency. The firm’s recent results have shown a gradual normalisation of volumes across Australia and Europe, with management emphasising the importance of workforce stabilisation and digital transformation. Ramsay’s long‑term tailwinds – ageing populations, rising chronic disease, and increased demand for surgical interventions; are all favourable.

The company’s unique FY27 narrative is shaped by capacity and efficiency. Ramsay has invested heavily in digital patient pathways, scheduling optimisation, and clinical workflow improvements. These initiatives should begin to yield productivity gains through FY27. Labour cost inflation remains a challenge, but management commentary suggests that the worst of the volatility has passed.

Challenger (ASX:CGF)

Challenger enters FY27 with structural tailwinds in retirement income, regulatory clarity, and improved distribution. The firm’s FY26 results highlighted strong annuity sales, driven by demographic trends and increased adviser engagement. The retirement income framework continues to support annuity adoption, and Challenger’s investment capabilities have strengthened following recent platform enhancements.

The FY27 outlook is shaped by interest rates and investor demand. As rates stabilise, annuity pricing becomes more predictable, supporting margin stability. Challenger’s funds management arm continues to grow, providing diversification beyond annuities. But even annuities are more attractive because flipping real estate isn’t as tax-effective as it has been for the last 26 years given Labor’s CGT changes.

Sandfire Resources (ASX:SFR)

Sandfire is another copper player on our list. You may remember it DeGrussa discovery, but these days it is known for its MATSA operations in Spain, and Motheo project in Botswana. Sandfire’s assets provide leverage to rising copper prices, and the firm’s exploration pipeline offers potential upside.

Management has guided to 149-166kt production for FY26, although it expects to reach the lower end of this range due to weather impacts in Spain and operational delays at Motheo. But the worst of the delays are behind it and the company has maintained strong margins.

AP Eagers (ASX:APE)

AP Eagers is Australia’s second largest car dealership group. The automotive retail sector has had a difficult few years normalised following years of supply constraints, and APE’s recent results have showed improved throughput and margin stability.

The firm’s diversified brand portfolio and national footprint provide resilience across market cycles. It is particularly benefiting from the popularity of BYD as APE is its primary retail partner in Australia – albeit no longer the exclusive one.

Sims (ASX:SGM)

Remember Metallium and the surge it had? It was all because its technology showed staunch potential to aid metals recycling as an alternative to building new mines. Sims is arguably the best large cap exposure to that trend. Sure, you could look at another small cap at the R&D phase, but Sims is a stable large cap in the space long before it was popular.

Sims is expecting $420-435m EBIT for FY26 and we wouldn’t be surprised to be higher guidance for FY27. Sims has invested heavily in digital optimisation, automation, and sustainability initiatives, all of which should support margin improvement.